Valneva SE (VALN) Common Equity (2020 - 2026)
Valneva SE's (VALN) quarterly Common Equity came in at $89.8 million in Q1 2026, down 51.29% year-on-year from $184.3 million in Q1 2025, and down 27.34% quarter-over-quarter from $123.6 million in Q4 2025.
Valneva SE (VALN) Common Equity (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Common Equity across 7 years of filings, most recently posting $89.8 million for Q1 2026.
- Common Equity for Q1 2026 came in at $89.8 million, down 51.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.8 million (down 51.29% YoY), and the FY2025 annual result was $123.6 million, down 36.19% from the prior year.
- Common Equity came in at $89.8 million for Q1 2026 at Valneva SE, down from $123.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $505.8 million in Q3 2022 to a low of $89.8 million in Q1 2026.
- The 5-year median for Common Equity is $189.0 million (2024), against an average of $203.5 million.
- Across the five-year window, Common Equity tumbled 66.1% in 2023 and jumped 40.37% in 2024, its largest moves.
- Valneva SE's Common Equity stood at $224.2 million in 2022, then tumbled by 38.47% to $138.0 million in 2023, then jumped by 40.37% to $193.7 million in 2024, then tumbled by 36.19% to $123.6 million in 2025, then slipped by 27.34% to $89.8 million in 2026.
- The last three Common Equity figures came in at $89.8 million (Q1 2026), $123.6 million (Q4 2025), and $175.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 89.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.80 Mn |
| Dec 31, 2025 | 123.58 Mn |
| Sep 30, 2025 | 175.92 Mn |
| Jun 30, 2025 | 211.03 Mn |
| Mar 31, 2025 | 184.35 Mn |
| Dec 31, 2024 | 193.69 Mn |
| Sep 30, 2024 | 238.83 Mn |
| Jun 30, 2024 | 179.06 Mn |
| Mar 31, 2024 | 205.57 Mn |
| Dec 31, 2023 | 137.99 Mn |
| Sep 30, 2023 | 171.48 Mn |
| Jun 30, 2023 | 207.67 Mn |
| Dec 31, 2022 | 224.25 Mn |
| Sep 30, 2022 | 505.79 Mn |
| Dec 31, 2021 | 195.14 Mn |
| Sep 30, 2021 | 387.64 Mn |
| Dec 31, 2020 | 92.31 Mn |